Minitran (Amitriptyline Hydrochloride, Perphenazine)

Amitriptyline Hydrochloride and Perphenazine, the active ingredients in Minitran, are a tricyclic antidepressant and a phenothiazine antipsychotic presented as oral tablets for oral use. They are indicated for the treatment of depressive disorders, schizophrenia, and psychotic depression in adult patients.

GNH USA supplies Minitran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with dedicated logistics support for timely delivery. The product is manufactured in the European Union under strict GMP standards, ensuring consistent quality and compliance with global regulatory requirements.

Minitran combines amitriptyline and perphenazine to address mood and psychotic disorders.

Depression: alleviates depressive symptoms and improves mood in major depressive disorder. Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. Psychotic depression: treats depressive episodes with psychotic features by targeting both serotonin/norepinephrine and dopamine pathways.

Minitran may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dry mouth - Constipation - Drowsiness or sedation - Weight gain

Serious or Rare Side Effects: - Agranulocytosis - Neuroleptic malignant syndrome - Cardiac arrhythmias, including QT prolongation

When prescribing Minitran, clinicians should consider several safety precautions to minimize risk.

Cardiac monitoring: assess ECG and QT interval before initiating therapy and periodically thereafter. Gradual discontinuation: taper the dose to avoid withdrawal symptoms and rebound depression. Elderly patients: use lower doses and monitor for anticholinergic effects and sedation. Concomitant MAO inhibitors: avoid use within 14 days of stopping an MAOI to prevent serotonin syndrome. Hepatic or renal impairment: adjust dose based on liver and kidney function tests. Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Minitran can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin syndrome and hypertensive crisis. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase amitriptyline plasma levels, raising toxicity risk. - Other QT‑prolonging agents (e.g., quinidine, haloperidol): may precipitate cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Alcohol: enhances central nervous system depression and may worsen drowsiness. - Antihypertensive drugs: perphenazine can potentiate hypotensive effects, requiring blood pressure monitoring. - Other serotonergic agents (e.g., tramadol, linezolid): increase risk of serotonin syndrome.